(All fields required)
Please enter a valid email.
Please enter your name.
Prasad Devarajan, MD Director, Division of Nephrology and Hypertension 513-636-4531 email@example.com
Director, Division of Nephrology and Hypertension
Medical Director, Stone Center
Director, Nephrology and Hypertension Clinical Laboratory
Louise M. Williams Endowed Chair
Professor, UC Department of Pediatrics
Clinical specialties: Acute kidney injury, nephrotic syndrome, kidney stones
Visit the Devarajan Lab.
Czech KA, Bennett M, Devarajan P. Distinct metalloproteinase excretion patterns in focal segmental glomerulosclerosis. Pediatr Nephrol. 2011 Jul 1.
Askenazi DJ, Koralkar R, Levitan EB, Goldstein SL, Devarajan P, Khandrika S, Mehta RL, Ambalavanan N. Baseline Values of Candidate Urine Acute Kidney Injury (AKI) Biomarkers Vary by Gestational Age in Premature Infants. Pediatr Res. 2011 Jun 3. Abraham BP, Frazier EA, Morrow WR, Blaszak RT, Devarajan P, Mitsnefes M, Bryant JC, Sachdeva R. Cystatin C and neutrophil gelatinase-associated lipocalin as markers of renal function in pediatric heart transplant recipients. Pediatr Transplant. 2011 Apr 25. Sundaram N, Bennett M, Wilhelm J, Kim MO, Atweh G, Devarajan P, Malik P. Biomarkers for early detection of sickle nephropathy. Am J Hematol. 2011 Jul;86(7):559-66. Devarajan P, Krawczeski C. In reply to 'antifibrinolytic use during cardiac and hepatic surgery makes tubular proteinuria-based early biomarkers poor tools to diagnose perioperative acute kidney injury'. Am J Kidney Dis. 2011 Jun;57(6):960-1. Piyaphanee N, Ma Q, Kremen O, Czech K, Greis K, Mitsnefes M, Devarajan P, Bennett MR. Discovery and initial validation of α 1-B glycoprotein fragmentation as a differential urinary biomarker in pediatric steroid-resistant nephrotic syndrome. Proteomics Clin Appl. 2011 Jun;5(5-6):334-42.
Li S, Krawczeski CD, Zappitelli M, Devarajan P, Thiessen-Philbrook H, Coca SG, Kim RW, Parikh CR; for the TRIBE-AKI Consortium. Incidence, risk factors, and outcomes of acute kidney injury after pediatric cardiac surgery: A prospective multicenter study. Crit Care Med. 2011 Jun;39(6):1493-1499. Krawczeski CD, Woo JG, Wang Y, Bennett MR, Ma Q, Devarajan P. Neutrophil gelatinase-associated lipocalin concentrations predict development of acute kidney injury in neonates and children after cardiopulmonary bypass. J Pediatr. 2011 Jun;158(6):1009-1015.e1.
Basu RK, Devarajan P, Wong H, Wheeler DS. An update and review of acute kidney injury in pediatrics. Pediatr Crit Care Med. 2011 May;12(3):339-47.
Devarajan P. Biomarkers for the early detection of acute kidney injury. Curr Opin Pediatr. 2011 Apr;23(2):194-200.
Bradley P. Dixon, MD Pediatric Nephrologist 513-636-4531 firstname.lastname@example.org
Assistant Professor, UC Department of Pediatrics
DNA damage response; DNA repair; hyperosmolal microenvironments; atypical hemolytic uremic syndrome; thrombotic microangiopathies; complement-mediated renal diseases.
Visit the Dixon Lab.
Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, Davies SM, Pluthero FG, Lu L, Laskin BL. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013 Sep 19;122(12):2003-7.
Siroky BJ, Yin H, Babcock JT, Lu L, Hellmann AR, Dixon BP, Quilliam LA, Bissler JJ. Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress. Am J Physiol Renal Physiol. 2012 Sep 15;303(6):F831-44.
Dixon BP, Henry J, Siroky BJ, Chu A, Groen PA, Bissler JJ. Cell Cycle Control and DNA Damage Response of Conditionally Immortalized Urothelial Cells. PLoS ONE. 2011 Jan 28;6(1):e16595.
Dixon BP, Hulbert JC, Bissler JJ. Tuberous sclerosis complex renal disease. Nephron Exp Nephrol. 2011;118(1):e15-20.Lo MM, Mo JQ, Dixon BP, Czech KA. Disseminated histoplasmosis associated with hemophagocytic lymphohistiocytosis in kidney transplant recipients. Am J Transplant. 2010 Mar;10(3):687-91. Dixon BP, Chu A, Henry J, Kim R, Bissler JJ. Increased cancer risk of augmentation cystoplasty: possible role for hyperosmolal microenvironment on DNA damage recognition. Mutat Res. 2009 Nov 2;670(1-2):88-95. Dixon BP, Lu L, Chu A, Bissler JJ. RecQ and RecG helicases have distinct roles in maintaining the stability of polypurine.polypyrimidine sequences. Mutat Res. 2008 Aug 25;643(1-2):20-8.
Dixon BP, McEnery P, Goebel J. Immunobiology of paediatric renal transplantation. Progress in Paediatric Urology. 2008;10:165-182.Bissler JJ, Dixon BP. A mechanistic approach to inherited polycystic kidney disease. Pediatr Nephrol. 2005 May;20(5):558-66. Dixon BP, Devarajan P, Mitsnefes M. Neonatal renovascular hypertension due to prenatal traumatic retroperitoneal hematoma. Pediatr Nephrol. 2005 May;20(5):670-2.
Jens W. Goebel, MD Clinical Director, Nephrology and Hypertension 513-636-4531 email@example.com
Clinical Director, Nephrology and Hypertension
Medical Director, Kidney Transplantation
Clinical Director, Kidney Transplantation
Organ transplantation in children
Sanchez-Pinto LN, Laskin BL, Jodele S, Hummel TR, Yin HJ, Goebel J. BK virus nephropathy in a pediatric autologous stem-cell transplant recipient. Pediatr Blood Cancer. 2011 Mar;56(3):495-7. Hooper DK, Carle AC, Schuchter J, Goebel J. Interaction between tacrolimus and intravenous nicardipine in the treatment of post-kidney transplant hypertension at pediatric hospitals. Pediatr Transplant. 2011 Feb;15(1):88-95. Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan 1;50(1):1-24.Campbell K, Ng V, Martin S, Magee J, Goebel J, Anand R, Martz K, Bucuvalas J; SPLIT Renal Function Working Group. Glomerular filtration rate following pediatric liver transplantation--the SPLIT experience. Am J Transplant. 2010 Dec;10(12):2673-82. Pai AL, Gray E, Kurivial K, Ross J, Schoborg D, Goebel J. The Allocation of Treatment Responsibility scale: a novel tool for assessing patient and caregiver management of pediatric medical treatment regimens. Pediatr Transplant. 2010 Dec;14(8):993-9.Jodele S, Bleesing JJ, Mehta PA, Filipovich AH, Laskin BL, Goebel J, Pinkard SL, Davies SM. Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2010 Nov 5. Pai AL, Ingerski LM, Perazzo L, Ramey C, Bonner M, Goebel J. Preparing for transition? The allocation of oral medication regimen tasks in adolescents with renal transplants. Pediatr Transplant. 2011 Feb;15(1):9-16. Laskin BL, Goebel J, Davies SM, Khoury JC, Bleesing JJ, Mehta PA, Filipovich AH, Paff ZN, Lawrence JM, Yin HJ, Pinkard SL, Jodele S. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2010 Aug 9.
Herzer M, Goebel J, Cortina S. Transitioning cognitively impaired young patients with special health needs to adult-oriented care: collaboration between medical providers and pediatric psychologists. Curr Opin Pediatr. 2010 Oct;22(5):668-72.
Fukuda T, Goebel J, Thøgersen H, Maseck D, Cox S, Logan B, Sherbotie J, Seikaly M, Vinks AA. Inosine Monophosphate Dehydrogenase (IMPDH) Activity as a Pharmacodynamic Biomarker of Mycophenolic Acid Effects in Pediatric Kidney Transplant Recipients. J Clin Pharmacol. 2010 Apr 23.
NIH UO1 grant: Noninvasive Monitoring to Predict Outcome in de novo Kidney Transplant Recipients (CTOT-01, Protocol Chair: P. Heeger, MD, City), commenced in late 2005 and ongoing
NIH UO1 grant: Health and Literacy in Child and Adult Assessment: Expanded Testing of the Pediatric PROMIS (Patient Reported Outcomes Measurement Information System) Tool (Sponsor: D. DeWalt, MD, MPH, ), ongoing.
NIH UO1 grant: Chronic Kidney Disease in Children (CKID, PI: B. Warady, MD, Children’s Mercy Hospital, Kansas City, MO), ongoing.
NIH RO1 grant: Calcineurin Inhibitor Minimization And Foxp3+ Tregs Post-Transplant (PIs: Wayne Hancock, MD, Children’s , and John Bucuvalas, MD, Cincinnati Children’s Hospital), ongoing.
Midwest Pediatric Nephrology Consortium: Assessing and Implementing Transition to Adult Care in Children with CKD (PI: M. Ferris, MD, MPH, PhD, ), ongoing
Amgen Pharmaceuticals: Pediatric Anemia Correction Study (Protocol 20050256), ongoing.
Roche Pharmaceuticals: Development of Population Pharmacokinetic models of Mycophenolic Acid for use in Bayesian Dose Individualization in Pediatric Kidney Transplant Patients (PI: A. Vinks, Cincinnati Children’s Hospital), ongoing.
Cincinnati Children’s Hospital Medical Center Outcomes Research Award: Validation of a Real-Time Adherence Assessment System (PI: A. Pai, PhD, Cincinnati Children’s Hospital), ongoing.
Cincinnati Children’s Hospital Medical Center Translational Research Initiative grant: Pharmacogenetics of Mycophenolic Acid in Kidney Transplant Patients (PI: A. Vinks, Cincinnati Children’s Hospital), ongoing.
Cincinnati Children’s Hospital Medical Center Translational Research Initiative grant: Biomarkers for Patient-tailored Therapies in Pediatric Lupus Nephritis using Mycophenolic Acid (PI: H. Brunner, Cincinnati Children’s Hospital), ongoing.
Cincinnati Children’s Hospital Medical Center Translational Research Initiative grant: Pharmacogenetics of IMPDH in Kidney Transplant Patients (PI: A. Vinks, Cincinnati Children’s Hospital), ongoing.
Stuart L. Goldstein, MD Director, Center for Acute Care Nephrology 513-803-3295 firstname.lastname@example.org
Director, Center for Acute Care Nephrology
Acute kidney injury; continuous renal replacement therapy; end-stage renal disease; health-related quality of life
Stuart L. Goldstein, MD, has been an active investigator in the field of pediatric acute kidney injury (AKI) since 2000. Dr. Goldstein’s main research foci include: AKI epidemiology and outcomes, acute renal replacement therapy provision and investigation of novel urinary AKI biomarkers in the pediatric population. Dr. Goldstein has established a strong record of interdisciplinary and inter-institutional collaboration with cardiologists, intensivists and emergency center physicians, which is evidenced by his establishment and directing of the Prospective Pediatric Continuous Renal Replacement Therapy Registry from 2001 to 2012, and the Prospective Pediatric AKI Research Group (ppAKI-RG) in 2012. The ppAKI-RG is comprised of 39 centers from around the world with the goal of improving outcomes for the child with or at-risk for, AKI.
Dr. Goldstein has led initial efforts to develop a standardized definition for pediatric AKI, assess novel AKI biomarkers in heterogeneous populations, and conceiving and validating stratification tools to identify patients at risk for AKI. Building up these findings, Dr. Goldstein embarked on establishing the ppAKI-RG consortium to focus on multi-centered research studies that are dedicated to understanding and treating AKI in pediatric patients. Currently, the ppAKI-RG has initiated three major, and unprecedented, national and international studies (AWARE, NINJA and DIRECT) to reduce AKI and improve patient outcomes. Dr. Goldstein is also a recognized educator; he has developed the only pediatric specific acute care nephrology sub-specialty fellowship with graduates who are now leaders in the field of pediatric AKI.
David K. Hooper, MD, MS Pediatric Nephrologist, Division of Nephrology 513-636-4531 email@example.com
Pediatric Nephrologist, Division of Nephrology
Nephrology; kidney transplantation; quality improvement
Jointly appointed in the Division of Nephrology and Hypertension and the James M. Anderson Center for Health Systems Excellence at Cincinnati Children’s Hospital, Dr. Hooper's aim is to improve clinical outcomes for pediatric kidney transplant recipients through research in personalized care and the design of reliable healthcare systems.
Dr. Hooper's research training includes a master's degree in clinical and translational research from the University of Cincinnati, in addition to advanced training in quality improvement methodology through the Quality Scholars in Healthcare Transformation program at Cincinnati Children’s Hospital Medical Center.
Dr. Hooper's career focus is to combine clinical outcomes research with quality improvement to reliably prevent cardiovascular disease, the leading cause of long-term death and disability in pediatric transplant recipients.
MD: University of Utah, Salt Lake City, Utah, 2003.
Residency: Cincinnati Children's Hospital, Cincinnati, Ohio, 2006.
Chief Residency: Cincinnati Children's Hospital, Cincinnati, Ohio, 2007.
MS: University of Cincinnati, Cincinnati, Ohio, 2010.
Fellowship: Cincinnati Children's Hospital, Cincinnati Ohio, 2010; Quality Scholar in Healthcare Transformation, James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital, Cincinnati, Ohio, 2011.
Certification: Pediatrics, 2006.
Hooper DK, Kirby C, Margolis P, Goebel J. Reliable Individualized Monitoring Improves Cholesterol Control in Kidney Transplant Recipients. Pediatrics. 2013 Apr;131(4):e1271-9.
Hooper DK, Williams JC, Carle AC, Amaral S, Chand DH, Ferris ME, Patel HP, Licht C, Barletta GM, Bastian V, Mitsnesfes M, Patel UD. The Quality of Cardiovascular Disease Care and Formal Transition for Adolescents with Kidney Disease. Pediatr Nephrol. 2013 Jun;28(6):939-49.
Hooper DK, Fukuda T, Logan B, Gardiner R, Roy-Chaudhury A, Kirby C, Vinks A, Goebel J. Risk of Tacrolimus Toxicity in CYP3A5 Non-Expressors Treated with Intravenous Nicardipine After Kidney Transplantation. Transplantation. 2012 Apr;93(8):806-812.
Saldaña SN, Hooper DK, Froehlich TE, Campbell KM, Prows CA, Sadhasivam s, Nick TG, Seid M, Vinks AA, Glauser TA. Characteristics of Successful Recruitment in Prospective Pediatric Pharmacogenetic Studies. Clinical Therapeutics. 2011 Feb;15:88-95.
Hooper DK, Carle AC, Schuchter J, Goebel J. Interaction between tacrolimus and intravenous nicardipine in the treatment of post-kidney transplant hypertension at pediatric hospitals. Pediatr Transplant. 2011 Feb;15(1):88-95.
Kaplan HC, Brady PW, Dritz MC, Hooper DK, Linam WM, Froehle CM, Margolis P. The influence of context on quality improvement success in health care: a systematic review of the literature. Milbank Q. 2010 Dec;88(4):500-59.
Hooper DK. The Impact of CYP3A5 Genotype on the Interaction Between Tacrolimus and Intravenous Nicardipine in Kidney Transplant Recipients. University of Cincinnati. 2010 Aug 17.
Hooper DK, Hawkins JA, Fuller TC, Profaizer T, Shaddy RE. Panel-reactive antibodies late after allograft implantation in children. Ann Thorac Surg. 2005 Feb;79(2):641-4. Raetz EA, Kim MK, Moos P, Carlson M, Bruggers C, Hooper DK, Foot L, Liu T, Seeger R, Carroll WL. Identification of genes that are regulated transcriptionally by Myc in childhood tumors. Cancer. 2003 Aug 15;98(4):841-53. Lirazan MB, Hooper D, Corpuz GP, Ramilo CA, Bandyopadhyay P, Cruz LJ, Olivera BM. The spasmodic peptide defines a new conotoxin superfamily. Biochemistry. 2000 Feb 22;39(7):1583-8.
Elizabeth C. Jackson, MD Director, Healthy Bladder Clinic 513-636-4975 firstname.lastname@example.org
Director, Healthy Bladder Clinic
Associate Professor, UC Department of Pediatrics
Elizabeth C. Jackson, MD, is a pediatric nephrologist recognized in the need for bladder management. Dr. Jackson has recently discontinued her inpatient nephrology role and is currently focused on outpatient lower urinary tract management. She is the director of the Healthy Bladder Clinic at Cincinnati Children's. The Healthy Bladder Clinic cares for children with functional lower urinary tract disorders. There are more than 1200 visits per year to this clinic.
Ivancić V, Defoor W, Jackson E, Alam S, Minevich E, Reddy P, Sheldon C. Progression of renal insufficiency in children and adolescents with neuropathic bladder is not accelerated by lower urinary tract reconstruction. J Urol. 2010 Oct;184(4 Suppl):1768-74.
DeFoor WR, Jackson E, Minevich E, Caillat A, Reddy P, Sheldon C, Asplin J. The risk of recurrent urolithiasis in children is dependent on urinary calcium and citrate. Urology. 2010 Jul;76(1):242-5.
DeFoor W, Clark C, Jackson E, Reddy P, Minevich E, Sheldon C. Risk factors for end stage renal disease in children with posterior urethral valves. J Urol. 2008 Oct;180(4 Suppl):1705-8; discussion 1708.
DeFoor W, Minevich E, Jackson E, Reddy P, Clark C, Sheldon C, Asplin J. Urinary metabolic evaluations in solitary and recurrent stone forming children. J Urol. 2008 Jun;179(6):2369-72.
DeFoor W, Asplin J, Jackson E, Jackson C, Reddy P, Sheldon C, Erhard M, Minevich E. Urinary metabolic evaluations in normal and stone forming children. J Urol. 2006 Oct;176(4 Pt 2):1793-6.
Defoor W, Asplin J, Jackson E, Jackson C, Reddy P, Sheldon C, Minevich E. Results of a prospective trial to compare normal urine supersaturation in children and adults. J Urol. 2005 Oct;174(4 Pt 2):1708-10.
Jensen S, Jackson EC, Riley L, Reddy S, Goebel J. Tacrolimus-based immunosuppression with steroid withdrawal in pediatric kidney transplantation -- 4-year experience at a moderate-volume center. Pediatr Transplant. 2003 7:119-124.
Strife CF, Prada AL, Clardy CW, Jackson E, Forristal J. Autoantibody to complement neoantigens in membranoproliferative glomerulonephritis. J Pediatr. 1990 May;116(5):S98-102.
Paul T. McEnery, MD, MBA 513-636-8652 email@example.com
Emeritus Professor of Pediatrics
Glomerulonephritis; vitamin D resistant rickets; care of the child with end-stage renal disease
DeFoor W, Tackett L, Minevich E, McEnery P, Kitchens D, Reeves D, Sheldon C. Successful renal transplantation in children with posterior urethral valves. J Urol. 2003 Dec;170(6 Pt 1):2402-4.
Mitsnefes M, Ho PL, McEnery PT. Hypertension and progression of chronic renal insufficiency in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). J Am Soc Nephrol. 2003 Oct;14(10):2618-22.
DeFoor W, Minevich E, McEnery P, Tackett L, Reeves D, Sheldon C. Lower urinary tract reconstruction is safe and effective in children with end stage renal disease. J Urol. 2003 Oct;170(4 Pt 2):1497-500; discussion 1500.
Mitsnefes MM, Khoury PR, McEnery PT. Early posttransplantation hypertension and poor long-term renal allograft survival in pediatric patients. J Pediatr. 2003 Jul;143(1):98-103.
Mitsnefes MM, Khoury P, McEnery PT. Body mass index and allograft function in pediatric renal transplantation. Pediatr Nephrol. 2002 Jul;17(7):535-9.
Omoloja AA, Racadio JM, McEnery PT. Post-biopsy renal arteriovenous fistula. Pediatr Transplant. 2002 Feb;6(1):82-5.
Mitsnefes MM, Omoloja A, McEnery PT. Short-term pediatric renal transplant survival: blood pressure and allograft function. Pediatr Transplant. 2001 Jun;5(3):160-5.
Schurman SJ, McEnery PT. Factors influencing short-term and long-term pediatric renal transplant survival. J Pediatr. 1997 Mar;130(3):455-62.
McEnery PT. Pediatric renal transplantation: A review of data from north American pediatric renal transplant cooperative study (NAPRTCS). Saudi J Kidney Dis Transpl. 1994 July-September;5(3):336-46.
McEnery PT, Alexander SR, Sullivan K, Tejani A. Renal transplantation in children and adolescents: the 1992 annual report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol. 1993 Dec;7(6):711-20.
Mark M. Mitsnefes, MD, MS Director, Clinical and Translational Research Center 513-636-0125 firstname.lastname@example.org
Director, Clinical and Translational Research Center
Nephrology with focus on chronic kidney disease and hypertension
Mark Mitsnefes, MD, MS, is an established clinical investigator with expertise in the area of understanding the development of risk factors for cardiovascular disease in children with chronic kidney disease. The long-term goal of his research is to define biologic targets for interventions to prevent and slow progression of cardiovascular disease in children with chronic kidney disease.
Dr. Misnefes has received numerous awards, including the Proctor Scolar Award (Cincinnati Children's Research Foundation), the Pediatrician Scientist Award (Children's Health Research Center, NIH), the Clinical Scientist Award (National Kidney Foundation), and has been ranked as one of the Best Doctors in America, 2007-2011.
MD: Gorky Medical Institute, Gorky, Russia, 1985.Residency: Miami Children's Hospital, Miami, Florida, 1997.Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 2000.
MS: Epidemiology and Biostatistics, University of Cincinnati, Cincinnati, Ohio, 2001.
Certifications: Educational Commission for Foreign Medical Graduates (ECFMG), 1995; Pediatrics, 1996; Pediatric Nephrology, 2001, 2008.
Mitsnefes M, Flynn J, Cohn S, Samuels J, Blydt-Hansen T, Saland J, Kimball T, Furth S, Warady B; CKiD Study Group. Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol. 2010 Jan;21(1):137-44.
Wilson AC, Mitsnefes MM. Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management. Am J Kidney Dis. 2009 Aug;54(2):345-60. Review.
Flynn JT, Mitsnefes MM, Pierce C, Cole SR, Parekh RS, Furth SL and Warady BA. Blood pressure in children with chronic kidney disease: Preliminary findings from chronic kidney disease in children cohort study. Hypertension. 2008;52(4):631-7
Weaver DJ Jr, Kimball T, Witt SA, Glascock BJ, Khoury PR, Kartal J, Mitsnefes MM. Subclinical systolic dysfunction in pediatric patients with chronic kidney disease. J Pediatr. 2008 Oct;153(4):565-9.
Weaver DJ Jr., Kimball TR, Knilans T, Mays WK, Knecht T, Gerdes YT, Witt S, Glascock BJ, Kartal J, Khoury PR, and Mitsnefes MM. Decreased maximal aerobic capacity in pediatric chronic kidney disease. J Am Soc Nephrol. 2008, 19(3):624-30.
Mitsnefes MM, Kimball TR, Kimball TR, Witt SA, Glascock BJ, Khoury PR, and Daniels SR. Abnormal carotid artery structure and function in children with successful renal transplant. Circulation. 2004; 110:97-101.
Mitsnefes MM, Kimball TR, Kartal J, Witt SA, Glascock B, Khoury PR, Daniels SR. Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: Role of calcium-phosphorus metabolism. J Am Soc Nephrol. 2005;16:2796-2803.
Mitsnefes MM, Kimball TR, Border WL, Witt SA, Glascock BJ, Khoury PR and Daniels SR. Impaired left ventricular diastolic function in children with chronic renal failure. Kidney Int. 2004;65(4):1461-1466.
Mitsnefes MM, Kimball TR, Witt SA, Glascock BJ, Khoury PR, and Daniels SR. Left ventricular mass and systolic performance in pediatric patients with chronic renal failure. Circulation. 2003;107:864-868
Mitsnefes MM, Daniels SR, Schwartz SM, Khoury P, Meyer RA, and Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol. 2000;14:898-902.
C. Frederic Strife, MD Emeritus Professor 513-636-4531 email@example.com
Director of the Dialysis Unit
MD: College of Medicine and Dentistry of New Jersey, 1968.
Residency: Pediatrics, Children's Hospital Medical Center, Cincinnati, OH.
Fellowship: Nephrology, Children's Hospital Medical Center, Cincinnati, OH.
Certification: Pediatrics, 1973; Pediatric Nephrology, 1976.
Calvo-Garcia MA, Campbell KM, O'Hara SM, Khoury P, Mitsnefes MM, Strife CF. Acquired renal cysts after pediatric liver transplantation: association with cyclosporine and renal dysfunction. Pediatr Transplant. 2008 Sep;12(6):666-71. Vo NJ, Hammelman BD, Racadio JM, Strife CF, Johnson ND, Racadio JM. Anatomic distribution of renal artery stenosis in children: implications for imaging. Pediatr Radiol. 2006 Oct;36(10):1032-6.
Brunner HI, Bishnoi A, Barron AC, Houk LJ, Ware A, Farhey Y, Mongey AB, Strife CF, Graham TB, Passo MH. Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus. Lupus. 2006;15(4):198-206. Mitsnefes MM, Subat-Dezulovic M, Khoury PR, Goebel J, Strife CF. Increasing incidence of post-kidney transplant anemia in children. Am J Transplant. 2005 Jul;5(7):1713-8. Omoloja AA, Kumar K, Crawford AH, Strife CF. Epiphyseal stapling and recombinant human growth hormone for correction of genu valgum in children with chronic renal insufficiency. J Pediatr Orthop. 2003 Sep-Oct;23(5):639-42.
Lande MB, Gullion C, Hoss RJ, Gauthier B, Shah B, Leonard MB, Bonilla-Felix M, Nash M, Roy S, Strife CF, Arbus G. Long versus standard initial steroid therapy for children with the nephrotic syndrome. A report from the Southwest Pediatric Nephrology Study. Pediatr Nephrol. 2003;18:342-6.
Chand DH, Rhoades T, Poe SA, Kraus S, Strife CF. Incidence and severity of vesicoureteral reflux in children related to age, gender, race and diagnosis. J Urol. 2003;170:1548-1550.
Chand DH, Poe SA, Strife CF. Venous pressure monitoring does not accurately predict access failure in children. Pediatr Nephrol. 2002;17:765-770.
Mitsnefes MM, Daniels SR, Schwartz SM, Khoury P, Strife CF. Changes in left ventricular mass in children and adolescents during chronic dialysis. Pediatr Nephrol. 2001 Apr;16(4):318-23.
Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury P, Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol. 2000 Sep;14(10-11):898-902.
Rene G. Van De Voorde III, MD Medical Director, Dialysis Unit 513-636-4531 firstname.lastname@example.org
Medical Director, Dialysis Unit
Dialysis; primarily infant dialysis; chronic kidney disease; acute kidney injury; hypertension
VanDeVoorde RG, Mitsnefes MM. Hypertension in chronic kidney disease in children. Advances in Chronic Kidney Disease. 2011.
Krawczeski CD, Vandevoorde RG, Kathman T, Bennett MR, Woo JG, Wang Y, Griffiths RE, Devarajan P. Serum cystatin C is an early predictive biomarker of acute kidney injury after pediatric cardiopulmonary bypass. Clin J Am Soc Nephrol. 2010 Sep;5(9):1552-7.
Alon US, VandeVoorde RG. Beneficial effect of cinacalcet in a child with familial hypocalciuric hypercalcemia. Pediatr Nephrol. 2010 Sep;25(9):1747-50.
Bredrup C, Matejas V, Barrow M, Bláhová K, Bockenhauer D, Fowler DJ, Gregson RM, Maruniak-Chudek I, Medeira A, Mendonça EL, Kagan M, Koenig J, Krastel H, Kroes HY, Saggar A, Sawyer T, Schittkowski M, Swietliński J, Thompson D, VanDeVoorde RG, Wittebol-Post D, Woodruff G, Zurowska A, Hennekam RC, Zenker M, Russell-Eggitt I. Ophthalmological aspects of Pierson syndrome. Am J Ophthalmol. 2008 Oct;146(4):602-611.
VanDe Voorde RG, Mitsnefes MM. Ambulatory blood pressure monitoring: a quest for truth. Pediatr Transplant. 2007 Feb;11(1):10-3.
Wuhl E, Kogan J, Zurowska A, Matejas V, VanDeVoorde RG, Aigner T, Wendler O, Lesniewska I, Bouvier R, Reis A, Weis J, Cochat P, Zenker M. Neuro-developmental deficits in Pierson (microcoria-congenital nephrosis) Syndrome. American Journal of Medical Genetics (A). 2007;143(4):311-9.
VanDeVoorde RG, Barletta G, Chand D, Dresner IG, Lane J, Leiser J, Lin JJ, Pan CG, Patel H, Valentini RP, Mitsnefes MM. Status of Blood Pressure Control in Children on Maintenance Hemodialysis: The Midwest Pediatric Nephrology Consortium (MWPNC) Study. Pediatric Nephrology. 2007;22(4):547-53.
VanDeVoorde R, Witte D, Kogan J, Goebel J. Pierson Syndrome: A Novel Cause of Congenital Nephrotic Syndrome. Pediatrics. 2006;118(2):E1-5.
Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared with Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subjects with Dialysis dependent Chronic Kidney Disease. Site Co-investigator. AMAG Pharmaceutical. Apr 2011 - present.
Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared with Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subjects with Non-dialysis dependent Chronic Kidney Disease. Site-Principal Investigator. AMAG Pharmaceuticals. Apr 2011 - present.
A Randomized, Open-label, Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCI in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis. Principal Investigator. AMGEN. Jul 2014 – present.
An Open-label, Single-arm Study to Assess the Safety and Tolerability of Cinacalcet HCI in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Years with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis. Principal Investigator. NAPRTCS. Mar 2012 – Mar 2016.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center